Kamada Ltd Dossier
|
SectorHealth Care IndustryBiotechnology Beta (adjusted)0.43 Intrinsic Value $11.19median of 6 methods · middle span $7-$24based on filings through 31 Dec 2025 Market Price $8.20Price as of 1 Oct 2026 UndervaluedIntrinsic value is 36% above the market price −50% · IV below pricenear fair value ±15%IV above price · +50% Data confidence Sign in to view data confidence Market Cap $473.2M Enterprise Value $409.3M Shares Outstanding 57.6M diluted Moat Rating Wide Next Earnings Date15 Nov 2026 Last ex-dividend23 Mar 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Kamada Ltd. (KMDA) presents a compelling investment opportunity as a vertically integrated specialty biopharmaceutical leader trading at a discounted valuation relative to its double-digit organic growth profile. The company has successfully transitioned to a highly profitable commercial-stage business, supported by a robust portfolio of six FDA-approved plasma-derived therapies and a growing distribution segment in Israel and the MENA region. With the implementation of a new annual cash dividend policy distributing at least 50% of net income and the recent FDA approval of its San Antonio plasma collection center, Kamada is well-positioned to accelerate both organic and M&A-driven growth. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$11.00 Mean target$13.00 High · most bullish analyst$15.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $11.0010% The bear case is defined by severe operational disruptions arising from escalating geopolitical conflicts in the Middle East, potential international trade tariffs affecting global shipments, or increased competitive pressures on key proprietary products such as Cytogam. Base CaseCentral scenario $13.0060% Matches the consensus meanThe base case assumes Kamada successfully achieves its reiterated fiscal 2026 guidance of $200 million to $205 million in revenue and $50 million to $53 million in adjusted EBITDA, representing 13% and 23% year-over-year growth respectively. Growth is supported by steady demand for core products like KEDRAB, GLASSIA, and VARIZIG, alongside stable royalty streams from Takeda. Bull CaseUpside scenario $15.0030% The bull case is driven by rapid commercial scaling of the newly approved San Antonio plasma center, successful expansion of the distribution business into the MENA region, and positive Phase 3 clinical data for inhaled AAT, which could unlock a $2 billion global market. Additionally, strategic M&A utilizing the company's strong cash position could accelerate top-line growth beyond current organic guidance. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |